Heron Therapeutics Inc
NASDAQ:HRTX
Intrinsic Value
Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. [ Read More ]
The intrinsic value of one HRTX stock under the Base Case scenario is 3.29 USD. Compared to the current market price of 2.77 USD, Heron Therapeutics Inc is Undervalued by 16%.
Valuation Backtest
Heron Therapeutics Inc
Run backtest to discover the historical profit from buying and selling HRTX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Heron Therapeutics Inc
Current Assets | 188.8m |
Cash & Short-Term Investments | 80.4m |
Receivables | 60.1m |
Other Current Assets | 48.2m |
Non-Current Assets | 33.7m |
PP&E | 25.6m |
Other Non-Current Assets | 8.1m |
Current Liabilities | 79.7m |
Accounts Payable | 3.2m |
Accrued Liabilities | 76.4m |
Non-Current Liabilities | 176.8m |
Long-Term Debt | 149.5m |
Other Non-Current Liabilities | 27.3m |
Earnings Waterfall
Heron Therapeutics Inc
Revenue
|
127m
USD
|
Cost of Revenue
|
-65.1m
USD
|
Gross Profit
|
61.9m
USD
|
Operating Expenses
|
-172.6m
USD
|
Operating Income
|
-110.6m
USD
|
Other Expenses
|
56k
USD
|
Net Income
|
-110.6m
USD
|
Free Cash Flow Analysis
Heron Therapeutics Inc
HRTX Profitability Score
Profitability Due Diligence
Heron Therapeutics Inc's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
Heron Therapeutics Inc's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
HRTX Solvency Score
Solvency Due Diligence
Heron Therapeutics Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Score
Heron Therapeutics Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
HRTX Price Targets Summary
Heron Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for HRTX is 6.89 USD with a low forecast of 5.05 USD and a high forecast of 9.45 USD.
Ownership
HRTX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
HRTX Price
Heron Therapeutics Inc
Average Annual Return | -26.43% |
Standard Deviation of Annual Returns | 47.56% |
Max Drawdown | -98% |
Market Capitalization | 416.3m USD |
Shares Outstanding | 150 285 000 |
Percentage of Shares Shorted | 19.48% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. The company is headquartered in San Diego, California and currently employs 302 full-time employees. The firm commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF (HTX-011), HTX-019, and HTX-034. HTX-011 is a dual-acting local anaesthetic that delivers a fixed-dose combination of the local anaesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. HTX-019 is an investigational agent for the prevention of postoperative nausea and vomiting. HTX-034 is a product candidate for postoperative pain management.
Contact
IPO
Employees
Officers
The intrinsic value of one HRTX stock under the Base Case scenario is 3.29 USD.
Compared to the current market price of 2.77 USD, Heron Therapeutics Inc is Undervalued by 16%.